Prognostic criteria in macular histoplasmic choroiditis.
1. Fifty percent of 22 patients "desensitized" to histoplasmin developed subsequent activity, as compared to 44% of 23 patients without "desensitization." 2. Prednisone-induced remission of subclinical activity in patients monitoring their own central fields appears to be the most rewarding therapy for these desperate patients.
D001128:Argon; D002833:Choroiditis / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D003888:Desensitization, Immunologic; D006659:Histoplasmin; D006660:Histoplasmosis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D053685:Laser Therapy; D008266:Macula Lutea / Q000473:pathology / Q000601:surgery; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012164:Retinal Diseases / Q000276:immunology / Q000601:surgery / Q000628:therapy; D014785:Vision, Ocular
D001128:Argon; D006659:Histoplasmin; D011241:Prednisone